Literature DB >> 22903956

Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension.

Marion Delcroix1, Anton Vonk Noordegraaf, Elie Fadel, Irene Lang, Gérald Simonneau, Robert Naeije.   

Abstract

In chronic thromboembolic pulmonary hypertension (CTEPH) increased pulmonary vascular resistance is caused by fibrotic organisation of unresolved thromboemboli. CTEPH mainly differs from pulmonary arterial hypertension (PAH) by the proximal location of pulmonary artery obliteration, although distal arteriopathy can be observed as a consequence of non-occluded area over-perfusion. Accordingly, there is proportionally more wave reflection in CTEPH, impacting on pressure and flow wave morphology. However, the time constant, i.e. resistance × compliance, is not different in CTEPH and PAH, indicating only trivial effects of proximal wave reflection on hydraulic right ventricular load. More discriminative is the analysis of the pressure decay after pulmonary arterial occlusion, which is more rapid in the absence of significant distal arteriopathy. Structure and function of the right ventricle show a similar pattern to right ventricular hypertrophy, namely dilatation and wall thickening, as well as loss of function in CTEPH and PAH. This is probably related to similar loading conditions. Hyperventilation with hypocapnia is characteristic of both PAH and CTEPH. Ventilatory equivalents for carbon dioxide, as a function of arterial carbon dioxide tension, conform to the alveolar ventilation equation in both conditions, indicating a predominant role of increased chemosensitivity. However, a slight increase in the arterial to end-tidal carbon dioxide tension gradient in CTEPH shows a contribution of increased dead space ventilation.

Entities:  

Mesh:

Year:  2012        PMID: 22903956     DOI: 10.1183/09031936.00047712

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  34 in total

1.  Pulmonary vascular morphology as an imaging biomarker in chronic thromboembolic pulmonary hypertension.

Authors:  F N Rahaghi; J C Ross; M Agarwal; G González; C E Come; A A Diaz; G Vegas-Sánchez-Ferrero; A Hunsaker; R San José Estépar; A B Waxman; G R Washko
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

2.  Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.

Authors:  Soundos Saleh; Reiner Frey; Corina Becker; Sigrun Unger; Georg Wensing; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

3.  Prevalence of coronary artery-pulmonary artery collaterals in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Noel S Lee; Daniel G Blanchard; Kirk U Knowlton; Anna M McDivit; Victor Pretorius; Michael M Madani; Peter F Fedullo; Kim M Kerr; Nick H Kim; David S Poch; William R Auger; Lori B Daniels
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

4.  Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension.

Authors:  Athanasios Charalampopoulos; J Simon R Gibbs; Rachel J Davies; Wendy Gin-Sing; Kevin Murphy; Karen K Sheares; Joanna Pepke-Zaba; David P Jenkins; Luke S Howard
Journal:  J Appl Physiol (1985)       Date:  2016-07-14

Review 5.  Chronic thromboembolic pulmonary hypertension.

Authors:  Karen M Olsson; Bernhard Meyer; Jan Hinrichs; Jens Vogel-Claussen; Marius M Hoeper; Serghei Cebotari
Journal:  Dtsch Arztebl Int       Date:  2014-12-12       Impact factor: 5.594

Review 6.  Right ventricle in acute and chronic pulmonary embolism (2013 Grover Conference series).

Authors:  Christian Gerges; Nika Skoro-Sajer; Irene M Lang
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

7.  The clinical value of assessing right ventricular diastolic function after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Hidenori Moriyama; Mitsushige Murata; Toshimitsu Tsugu; Takashi Kawakami; Masaharu Kataoka; Takahiro Hiraide; Mai Kimura; Sarasa Isobe; Jin Endo; Takashi Kohno; Yuji Itabashi; Keiichi Fukuda
Journal:  Int J Cardiovasc Imaging       Date:  2017-12-30       Impact factor: 2.357

8.  Emerging hemodynamic signatures of the right heart (Third International Right Heart Failure Summit, part 2).

Authors:  Bradley A Maron
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

9.  Patient-specific finite element analysis of heart failure and the impact of surgical intervention in pulmonary hypertension secondary to mitral valve disease.

Authors:  Alireza Heidari; Khalil I Elkhodary; Cristina Pop; Mohamed Badran; Hojatollah Vali; Yousof M A Abdel-Raouf; Saeed Torbati; Masoud Asgharian; Russell J Steele; Iradj Mahmoudzadeh Kani; Sara Sheibani; Hamidreza Pouraliakbar; Hakimeh Sadeghian; Renzo Cecere; Matthias G W Friedrich; Hossein Ahmadi Tafti
Journal:  Med Biol Eng Comput       Date:  2022-04-20       Impact factor: 2.602

10.  Riociguat Improves Pulmonary Hemodynamics in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Cheng-Hsuan Tsai; Cho-Kai Wu; Ping-Hung Kuo; Hsao-Hsun Hsu; Zheng-Wei Chen; Juey-Jen Hwang; Chi-Lun Ko; Yu-Sen Huang; Yen-Hung Lin
Journal:  Acta Cardiol Sin       Date:  2020-01       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.